Milind A. Phadnis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Milind A. Phadnis has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Lauren Elizabeth Nye
University of Kansas Cancer Center
12 shared publications Manana Elia
City of Hope Cancer Center, Duarte, CA
12 shared publicationsMarc Hoffmann
University of Kansas Cancer Center, Westwood, KS
12 shared publicationsStephanie LaFaver
University of Kansas Health System, Kansas City, KS
12 shared publications- Stephen K. Williamson
University of Kansas Medical Center, Westwood, KS
12 shared publications - Andrew K. Godwin
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA
11 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71591
The impact of cognitive behavioral therapy for insomnia on cognitive performance and amyloid beta in older adults: A randomized controlled trial
INTRODUCTION: Insomnia is associated with increased risk for Alzheimer's disease (AD). It is unknown how cognitive behavioral therapy for insomnia (CBT‐I) impacts two hallmarks of AD progression, cognitive performance and beta‐amyloid (Aβ) burden. METHODS: Cognitively normal older adults with symptoms of insomnia were randomized into CBT‐I treatment ( n = 100) or control ( n = 100) groups. Cognitive performance was assessed at baseline, 6‐weeks, and 1‐year (1 year). Aβ burden was assessed in a subsample ( n = 50). RESULTS: No differences were observed between groups in change in cognitive performance, including speed of information processing (mean difference, 0.017; 95% confidence interval [CI], −0.1036 to 0.1376; p = 0.78), executive function (−0.0881; 95% CI, −0.2945 to 0.1182; p = 0.40), and memory (0.4068; 95% CI, −2.3965 to 3.2101; p = 0.77). No group differences were observed in Aβ deposition. DISCUSSION: CBT‐I did not improve cognitive performance or Aβ deposition by one year. Longer follow up is needed to understand the potential impact of CBT‐I on AD risk. CLINICAL TRIAL REGISTRATION: The study was registered on clinicaltrials.gov (NCT03954210) on 5/17/2019.
- 15 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71591
Open AccessThe impact of cognitive behavioral therapy for insomnia on cognitive performance and amyloid beta in older adults: A randomized controlled trial
INTRODUCTION: Insomnia is associated with increased risk for Alzheimer's disease (AD). It is unknown how cognitive behavioral therapy for insomnia (CBT‐I) impacts two hallmarks of AD progression, cognitive performance and beta‐amyloid (Aβ) burden. METHODS: Cognitively normal older adults with symptoms of insomnia were randomized into CBT‐I treatment ( n = 100) or control ( n = 100) groups. Cognitive performance was assessed at baseline, 6‐weeks, and 1‐year (1 year). Aβ burden was assessed in a subsample ( n = 50). RESULTS: No differences were observed between groups in change in cognitive performance, including speed of information processing (mean difference, 0.017; 95% confidence interval [CI], −0.1036 to 0.1376; p = 0.78), executive function (−0.0881; 95% CI, −0.2945 to 0.1182; p = 0.40), and memory (0.4068; 95% CI, −2.3965 to 3.2101; p = 0.77). No group differences were observed in Aβ deposition. DISCUSSION: CBT‐I did not improve cognitive performance or Aβ deposition by one year. Longer follow up is needed to understand the potential impact of CBT‐I on AD risk. CLINICAL TRIAL REGISTRATION: The study was registered on clinicaltrials.gov (NCT03954210) on 5/17/2019.
- 24 May 2026
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- p. 1-13
Optimizing rare neurological disease trials: Bayesian frameworks and hierarchical models for improved efficiency in clinical trial design
While traditionally used in early-phase oncology trials, we explore the benefits of Bayesian methods in clinical trial design, emphasizing their application in rare neurological disease trials. Focusing in this report on a potential redesign of the Phase II trial of SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP), we compare the performance of the original design to two potential optimization alternatives. First, we retained continuous outcomes to preserve information. In the second modification, we propose the use of information borrowing through Bayesian hierarchical models (BHM). BHM for subgroup analysis increase precision in individual subpopulations by borrowing information from the whole study population and pooling individual estimates towards the overall estimate. Such models are used in basket trials which aim to evaluate a single targeted therapy across multiple settings that share a common characteristic. We found that the proposed optimizations demonstrate notable power gains. We advocate enhancing the efficiency of neurological disorders research through the implementation of this optimized Bayesian approach.
- 24 May 2026
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- p. 1-13
Optimizing rare neurological disease trials: Bayesian frameworks and hierarchical models for improved efficiency in clinical trial design
While traditionally used in early-phase oncology trials, we explore the benefits of Bayesian methods in clinical trial design, emphasizing their application in rare neurological disease trials. Focusing in this report on a potential redesign of the Phase II trial of SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP), we compare the performance of the original design to two potential optimization alternatives. First, we retained continuous outcomes to preserve information. In the second modification, we propose the use of information borrowing through Bayesian hierarchical models (BHM). BHM for subgroup analysis increase precision in individual subpopulations by borrowing information from the whole study population and pooling individual estimates towards the overall estimate. Such models are used in basket trials which aim to evaluate a single targeted therapy across multiple settings that share a common characteristic. We found that the proposed optimizations demonstrate notable power gains. We advocate enhancing the efficiency of neurological disorders research through the implementation of this optimized Bayesian approach.
- Open Access
- 26 November 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (2) , 102012
A phase 1b study on the safety of Wharton’s jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease
- 26 November 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (2) , 102012
Open AccessA phase 1b study on the safety of Wharton’s jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease
- Open Access
- 4 March 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 248, 116287
From past to present: A comparison of interpersonal firearm violence between historically graded neighborhoods of Kansas City
- 4 March 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 248, 116287
Open AccessFrom past to present: A comparison of interpersonal firearm violence between historically graded neighborhoods of Kansas City
- Open Access
- 13 January 2025
- Published by Wiley in Transfusion
- Vol. 65 (3) , 496-504
ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate
Background: Allocating incompatible platelet components to avoid product wastage must be balanced against the risk of reduced efficacy and adverse outcomes. The impact of platelet compatibility in association with product irradiation or pathogen reduction is unknown. This study aims to determine the combined and independent impact of platelet compatibility and component modification on transfusion reaction rate.Study Design and Methods: A retrospective review of all adult platelet transfusions from 2020 to 2022 was performed, including all reported reactions. Logistic regression was performed to evaluate the significance of ABO compatibility and unit modification for reaction rate.Results: Out of 21,330 transfusions to 3450 patients, 285 (1.33%) reactions were reported and 178 (0.83%) were diagnosed as related to transfusion, predominantly febrile nonhemolytic (n = 59) and allergic (n = 102). The compatibility of transfusion was 67.7% ABO identical, 13.8% ABO minor incompatible, 17.2% ABO major incompatible, and 1.4% ABO bidirectionally incompatible. Irradiated, unmodified, and pathogen‐reduced single‐donor platelets were transfused in 70.9%, 21.8%, and 7.3% of cases, respectively. Univariable regression demonstrated increased odds of reaction for major incompatibility vs. ABO identical (OR: 1.92; 95% CI: 1.36–2.71) and irradiated vs. unmodified (OR: 2.34; 95% CI: 1.45–3.91), which were confirmed by multivariable analysis. The effect of compatibility and unit modification were independent in all analyses.Conclusions: The results demonstrate a trend of increasing reaction rate associated with major incompatibility and product irradiation. This study provides additional data to inform institutional policies guiding product selection for individual patients.
- 13 January 2025
- Published by Wiley in Transfusion
- Vol. 65 (3) , 496-504
Open AccessABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate
Background: Allocating incompatible platelet components to avoid product wastage must be balanced against the risk of reduced efficacy and adverse outcomes. The impact of platelet compatibility in association with product irradiation or pathogen reduction is unknown. This study aims to determine the combined and independent impact of platelet compatibility and component modification on transfusion reaction rate.Study Design and Methods: A retrospective review of all adult platelet transfusions from 2020 to 2022 was performed, including all reported reactions. Logistic regression was performed to evaluate the significance of ABO compatibility and unit modification for reaction rate.Results: Out of 21,330 transfusions to 3450 patients, 285 (1.33%) reactions were reported and 178 (0.83%) were diagnosed as related to transfusion, predominantly febrile nonhemolytic (n = 59) and allergic (n = 102). The compatibility of transfusion was 67.7% ABO identical, 13.8% ABO minor incompatible, 17.2% ABO major incompatible, and 1.4% ABO bidirectionally incompatible. Irradiated, unmodified, and pathogen‐reduced single‐donor platelets were transfused in 70.9%, 21.8%, and 7.3% of cases, respectively. Univariable regression demonstrated increased odds of reaction for major incompatibility vs. ABO identical (OR: 1.92; 95% CI: 1.36–2.71) and irradiated vs. unmodified (OR: 2.34; 95% CI: 1.45–3.91), which were confirmed by multivariable analysis. The effect of compatibility and unit modification were independent in all analyses.Conclusions: The results demonstrate a trend of increasing reaction rate associated with major incompatibility and product irradiation. This study provides additional data to inform institutional policies guiding product selection for individual patients.
- Open Access
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2) , e2400068
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial
PURPOSE: In metastatic breast cancer (MBC), oral capecitabine prescribed at the US Food and Drug Administration (FDA)–approved dose of 1,250 mg/m 2 twice daily, 14 days on, 7 days off, is associated with poor tolerance. Mathematical models suggest that a fixed-dose (FD), dose-dense schedule may optimize efficacy. We conducted a randomized, open-label trial to compare the efficacy and tolerability of FD capecitabine, 1,500 mg twice daily, 7 days on, 7 days off (FD-7/7), with the FDA-approved dose and schedule (standard-dose [SD]-14/7). METHODS: Females with MBC and any previous lines of therapy were included. Patients were randomly assigned 1:1 to either FD-7/7 or SD-14/7. The primary end point was 3-month progression-free survival (PFS). Capecitabine-related toxicities were graded at each visit. RESULTS: Between October 2015 and April 2021, 153 patients were enrolled (n = 80 FD-7/7, n = 73 SD-14/7). The 3-month PFS was 63.1% (95% CI, 52.0 to 74.2) in the FD-7/7 arm and 67.2% (95% CI, 54.5 to 79.9) in the SD-14/7 arm. Restricted mean survival time was used to report estimates of effect. The PFS (restricted mean) at 33 months was 10.1 months (95% CI, 7.6 to 12.6) in the FD-7/7 arm compared with 9.1 months (95% CI, 6.6 to 11.7) in the SD-14/7 arm. The overall survival (restricted mean) at 80 months was 30.6 months (95% CI, 23.6 to 37.6) in the FD-7/7 arm versus 24.5 months (95% CI, 18 to 31.1) in the SD-14/7 arm. Toxicity-related treatment discontinuation occurred in 24 patients (32.9%) in the SD-14/7 arm compared with seven patients (8.8%) in the FD-7/7 arm ( P = .0002). Grade 2 to 4 toxicities occurred in 79.5% in the SD-14/7 arm compared with 37.5% in the FD-7/7 arm ( P < .0001). CONCLUSION: In MBC, FD capecitabine 1,500 mg twice daily on a 7/7 schedule has less toxicity and similar efficacy when compared with body surface area-based dosing on a 14/7 schedule.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2) , e2400068
Open AccessRandomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial
PURPOSE: In metastatic breast cancer (MBC), oral capecitabine prescribed at the US Food and Drug Administration (FDA)–approved dose of 1,250 mg/m 2 twice daily, 14 days on, 7 days off, is associated with poor tolerance. Mathematical models suggest that a fixed-dose (FD), dose-dense schedule may optimize efficacy. We conducted a randomized, open-label trial to compare the efficacy and tolerability of FD capecitabine, 1,500 mg twice daily, 7 days on, 7 days off (FD-7/7), with the FDA-approved dose and schedule (standard-dose [SD]-14/7). METHODS: Females with MBC and any previous lines of therapy were included. Patients were randomly assigned 1:1 to either FD-7/7 or SD-14/7. The primary end point was 3-month progression-free survival (PFS). Capecitabine-related toxicities were graded at each visit. RESULTS: Between October 2015 and April 2021, 153 patients were enrolled (n = 80 FD-7/7, n = 73 SD-14/7). The 3-month PFS was 63.1% (95% CI, 52.0 to 74.2) in the FD-7/7 arm and 67.2% (95% CI, 54.5 to 79.9) in the SD-14/7 arm. Restricted mean survival time was used to report estimates of effect. The PFS (restricted mean) at 33 months was 10.1 months (95% CI, 7.6 to 12.6) in the FD-7/7 arm compared with 9.1 months (95% CI, 6.6 to 11.7) in the SD-14/7 arm. The overall survival (restricted mean) at 80 months was 30.6 months (95% CI, 23.6 to 37.6) in the FD-7/7 arm versus 24.5 months (95% CI, 18 to 31.1) in the SD-14/7 arm. Toxicity-related treatment discontinuation occurred in 24 patients (32.9%) in the SD-14/7 arm compared with seven patients (8.8%) in the FD-7/7 arm ( P = .0002). Grade 2 to 4 toxicities occurred in 79.5% in the SD-14/7 arm compared with 37.5% in the FD-7/7 arm ( P < .0001). CONCLUSION: In MBC, FD capecitabine 1,500 mg twice daily on a 7/7 schedule has less toxicity and similar efficacy when compared with body surface area-based dosing on a 14/7 schedule.
- 18 August 2024
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (1)
Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters
Stochastic curtailment tests for Phase II two‐arm trials with time‐to‐event end points are traditionally performed using the log‐rank test. Recent advances in designing time‐to‐event trials have utilized the Weibull distribution with a known shape parameter estimated from historical studies. As sample size calculations depend on the value of this shape parameter, these methods either cannot be used or likely underperform/overperform when the natural variation around the point estimate is ignored. We demonstrate that when the magnitude of the Weibull shape parameters changes, unblinded interim information on the shape of the survival curves can be useful to enrich the final analysis for reestimation of the sample size. For such scenarios, we propose two Bayesian solutions to estimate the natural variations of the Weibull shape parameter. We implement these approaches under the framework of the newly proposed relative time method that allows nonproportional hazards and nonproportional time. We also demonstrate the sample size reestimation for the relative time method using three different approaches (internal pilot study approach, conditional power, and predictive power approach) at the interim stage of the trial. We demonstrate our methods using a hypothetical example and provide insights regarding the practical constraints for the proposed methods.
- 18 August 2024
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (1)
Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters
Stochastic curtailment tests for Phase II two‐arm trials with time‐to‐event end points are traditionally performed using the log‐rank test. Recent advances in designing time‐to‐event trials have utilized the Weibull distribution with a known shape parameter estimated from historical studies. As sample size calculations depend on the value of this shape parameter, these methods either cannot be used or likely underperform/overperform when the natural variation around the point estimate is ignored. We demonstrate that when the magnitude of the Weibull shape parameters changes, unblinded interim information on the shape of the survival curves can be useful to enrich the final analysis for reestimation of the sample size. For such scenarios, we propose two Bayesian solutions to estimate the natural variations of the Weibull shape parameter. We implement these approaches under the framework of the newly proposed relative time method that allows nonproportional hazards and nonproportional time. We also demonstrate the sample size reestimation for the relative time method using three different approaches (internal pilot study approach, conditional power, and predictive power approach) at the interim stage of the trial. We demonstrate our methods using a hypothetical example and provide insights regarding the practical constraints for the proposed methods.
- Open Access
- 27 May 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 40, 101315
Group sequential design for time-to-event outcome with non-proportional hazards using the concept of relative time utilizing two different Weibull distributions
- 27 May 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 40, 101315
Open AccessGroup sequential design for time-to-event outcome with non-proportional hazards using the concept of relative time utilizing two different Weibull distributions
- 14 August 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (4) , 596-611
Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards
As part of the drug development process, interim analysis is frequently used to design efficient phase II clinical trials. A stochastic curtailment framework is often deployed wherein a decision to continue or curtail the trial is taken at each interim look based on the likelihood of observing a positive or negative treatment effect if the trial were to continue to its anticipated end. Thus, curtailment can take place due to evidence of early efficacy or futility. Traditionally, in the case of time-to-event endpoints, interim monitoring is conducted in a two-arm clinical trial using the log-rank test, often with the assumption of proportional hazards. However, when this is violated, the log-rank test may not be appropriate, resulting in loss of power and subsequently inaccurate sample sizes. In this paper, we propose stochastic curtailment methods for two-arm phase II trial with the flexibility to allow non-proportional hazards. The proposed methods are built utilizing the concept of relative time assuming that the survival times in the two treatment arms follow two different Weibull distributions. Three methods - conditional power, predictive power and Bayesian predictive probability - are discussed along with corresponding sample size calculations. The monitoring strategy is discussed with a real-life example.
- 14 August 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (4) , 596-611
Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards
As part of the drug development process, interim analysis is frequently used to design efficient phase II clinical trials. A stochastic curtailment framework is often deployed wherein a decision to continue or curtail the trial is taken at each interim look based on the likelihood of observing a positive or negative treatment effect if the trial were to continue to its anticipated end. Thus, curtailment can take place due to evidence of early efficacy or futility. Traditionally, in the case of time-to-event endpoints, interim monitoring is conducted in a two-arm clinical trial using the log-rank test, often with the assumption of proportional hazards. However, when this is violated, the log-rank test may not be appropriate, resulting in loss of power and subsequently inaccurate sample sizes. In this paper, we propose stochastic curtailment methods for two-arm phase II trial with the flexibility to allow non-proportional hazards. The proposed methods are built utilizing the concept of relative time assuming that the survival times in the two treatment arms follow two different Weibull distributions. Three methods - conditional power, predictive power and Bayesian predictive probability - are discussed along with corresponding sample size calculations. The monitoring strategy is discussed with a real-life example.